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ABSTRACT
Advancing The Ability To Predict Cognitive Decline and Alzheimer’s Disease
Based On Genetic Variants Beyond Amyloid-b and Tau
By Naveen Rawat
A growing amount of neurodegenerative R&D is focused on identifying genomicbased explanations of AD that are beyond Amyloid-b and Tau. The proposed effort
involves identifying some of the genomic variations, such as single nucleotide
polymorphisms (SNPs), allele , chromosome, epigenetic contributors to MCI and
AD that are beyond Aβ and Tau.
The project involves building a prediction model based on a support vector machine
(SVM) classifier that takes into account the genomic variations and epigenetic
factors to predict the early stage of mild cognitive impairment (MCI) and Alzheimer
disease (AD). To achieve this, picking up important feature sets which will be input
to the machine learning model were identified using statistical model tests. The data
used in this research were obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database / ADNI GO2 GWAS.
Future work may involve increase in sample size analyzed from ADNI DB, explore
and analyze potential secondary effects/medical-conditions such as other diseases
that might have influenced the observed results and separate out MCI from AD and
further explore predictions and results.
Key Words: SNP Name, Allele1 - Plus, Allele2 - Plus, Chromosome, SNP
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INTRODUCTION
Alzheimer’s Disease (AD) is a type of dementia that is a neurovegetative disorder
which impacted approximately 47 million or 0.6% of the global population in 2015
(Rawtaer et al., 2020). The number of AD diagnoses is projected to triple by 2050
(Rawtaer et al., 2020). More than 6 million Americans of any age have Alzheimer's
(Lawlor, B. A. et al. ,1994). An anticipated 6.2 million Americans age sixty-five and
older are residing with Alzheimer's dementia by 2021. Seventy- percentage are age
seventy-five or older. One in nine human beings age sixty-five and older (11.3%) in
America has Alzheimer's dementia (Dianxu Ren str al., 2020).

The global costs of dementia in 2015 were estimated at $818 billion, a 35.4%
increase compared with 2010. Up to 1 in 5 of the community-dwelling older adults
aged 65 years and above suffer from mild cognitive impairment (MCI). Between
10–15% of patients with MCI may develop dementia each year (Davis & Allen,
2013). In addition, a recent meta-analysis indicated that about 45% of MCI patients
maintained stable cognitive ability, whereas 28% progressed to AD and 15%
returned to normal status without recurrence (Hu et al., 2017). These are pandemic
numbers and costs.

AD is an irreversible, fast-spreading brain disease that slowly destroys memory,
critical thinking capabilities and, eventually, the capacity to perform simple tasks
that are needed to maintain independence. Most human beings with the disorder
signs and symptoms first seem to be in their mid-60s (Lawlor, B. A. et al. ,1994).
MCI causes a mild, however great and measurable, decline in cognitive abilities,
together with memory and questioning skills. An individual with MCI is at an
accelerated danger of growing Alzheimer's or any other dementia.[1]
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In recent years, there has been significant efforts to develop biomarkers that can help
with the early detection of AD and MCI [2]. These efforts can be roughly partitioned
into approaches that are (1) non-neuroimaging; (2) neuroimaging; (3) brain volumebased; and (4) genomic-epigenetic-based in nature. Example non-neuroimaging
work to identify MCI and AD biomarkers typically involve evaluating metrics such
as cerebrospinal fluid (CSF), positron emission tomography (PET), and plasma, βamyloid, total tau (T-tau), and phosphorylated tau (Ptau) (Gao et al., 2021; Van et
al., 2020). Additional non-neuroimaging metrics include differentially methylated
positions (DMPs) as novel blood-based biomarkers of AD (Vasanthakumar et al.,
2020). Example neuroimaging work to identify MCI and AD biomarkers involve
evaluating metrics such as an analysis of MRI images (Stamate et al., 2020; C.B.
Hall et al., 2009; Patnode et al., 2020). Example brain volume-based work to identify
AD and MCI biomarkers include the work of Kotb’s group, (Kotb et al., 2020).

The results of work presented here lies within the category of genomic-epigeneticbased approaches, and is beyond the well known Aβ and Tau based biomarkers
which is the focus of groups such as Gao and Van (Gao et al., 2021; Van et al., 2020).
Rather, related example work that falls within the category is that from Kim’s group
(Kim et al., 2020). That is, excessive levels of Aβ and tau are not sufficient to
diagnose or explain all instances of AD. Previous work has reported that between
30% and 40% of normal individuals showed high levels of Aβ and tau (Bennett et
al., 2006; Mintun et al., 2006).
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In addition, despite high levels of tau showing a greater correlation with increased
cognitive dysfunction than Aβ, taken together both have a relatively weak
correlation with the degree of cognitive function. Furthermore, although tau
accumulation showed a higher association with cognitive dysfunction than did Aβ,
both pathogenic proteins demonstrated a weak to moderate association with the
degree of cognitive function (Driscoll et al., 2011;

Giannakopoulos et al.,

2003).There must be, therefore, other pathogenic contributors, beyond Aβ and tau,
that can contribute to the onset and progression of AD.

BACKGROUND
The current diagnostic methods and symptoms related to AD are presented in many
concluded research studies that clearly identifies Brain Amyloid-b (Aβ), in elevated
amounts found in brains. As per them Amyloid-b is the main component of deposits
that are found in the brains of patients with cognitive impairment (CI) and
Alzheimer's disease (AD) (Dianxu Ren et al. 2020; Lianne M. Reus et al. 2020; Zhu,
Xc. et al. 2020).
However, relatively recent research has found that AD appears only if Aβ is followed
by elevated levels of Tau (HangRai Kim et al. 2020). That is, AD does not appear in
the absence of elevated Tau levels. (Rubinski et al. Alzheimer's Research & Therapy
202)
Genetic studies of Alzheimer's disease (AD) indicate that β-amyloid is important in
the pathogenesis of the disease. However, amyloid-directed therapy usually does not
slow down the development of patients with symptomatic diseases. (William J. Ray
et al. Annu. Rev. Med. 2021. 72:15–28)
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Despite many advances of the past two decades, the cause of many cognitive
impairments (CI) and potent treatments remain puzzling to find. The hypothesis that
amyloid- (A) peptides are the key causative agents of CI holds dominant among
current researchers.
Nevertheless, many existing research studies show evidence that A peptides are
certainly not to be the only factor in AD etiology. A view of AD pathogenesis that
encompasses both the amyloid-dependent and amyloid-independent mechanisms
will help fill the gaps in knowledge and reconcile the findings that cannot be
explained solely by the amyloid hypothesis.

The search for purposeful CI and AD biomarkers remains wide and extensive. Many
different academic as well as industry R&D sectors have and continue to make
significant progress toward identifying CI and AD biomarkers.
One of many technical gaps that remains, despite successful previous work to date,
is the identification and characterization of additional genomic and epigenetic
factors that are correlated with CI and AD.
Having expanded knowledge about the genomic factors related to CI and AD is
expected to be the basis of more robust biomarkers for these neurodegenerative
diseases. Better and earlier detection of CI and AD can lead to earlier treatment,
better outcomes, and lower costs associated with the diseases.
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The research proposal here is to identify and characterize some of the
genomic variations, such as single nucleotide polymorphisms (SNPs),
allele, chromosome, epigenetic contributors to CI and AD that are beyond
Aβ and Tau, which is present in most of the existing works.

DATA
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is an initiative of
researchers who study data as they work to define the progression of Alzheimer’s
disease (AD). ADNI researchers collect, validate and utilize data, including MRI
and PET images, genetics, cognitive test and other biomarkers as predictors of the
cognitive impairment. Study resources and data from the North American ADNI
study are available through website login of adni.loni.usc.edu. These data include
Alzheimer’s disease patients, mild cognitive impairment subjects, and elderly
controls.

The datasets that are used for the project ADNI GO2_GWAS / Alzheimer's Disease
Neuroimaging Initiative (Grand Opportunities) Genome-wide association study.

The ADNI Genetics Core has released GWAS data for ADNI GO/2
participants which is available from the download section. Due to the
large volume of data, the 750 individual subject files have been
compressed into 15 zip files. In total around 735 subjects were analysed
for this research project.
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APPROACH AND METHOD
To develop any predictive model, the first step is the identifying strong features set
or input variables for the machine learning model with which reduces cost and time
complexity, also better model performance can be achieved.
Hence feature selection is an important criteria for success for any machine learning
ML / SVM model. It can also be said as the process of reducing the number of input
variables when developing a predictive model.
Statistical-based feature selection methods, for example Chi-Square and correlation
analysis involve evaluating the relationship between each input variable and the
output or the response variable using statistics and selecting those features that have
the strongest relationship with the response variable. These Statistical-based
methods are standard industry based practices and are fast and effective, also here
the adoption of these mentioned statistical methods were governed by choice of the
data sets used ADNI GO2 GWAS for both the input and response variables. As
explained above, the Chi-Square test of independence and collreation test were used
to decide if there's a considerable relationship among two specific input / output
variables.
Furthermore, compare the frequency of each category of input variable with the type
of the output variable. The statistical information is displayed in a contingency table,
with each row representing the category of a variable and each column representing
the category of the opposite variable. It can be said that researchers want to
investigate the relationship between different category cognitive impairment Groups
(CN 0, MCI 1, AD 2 ) versus genomic variations; Allele 1 & 2 Plus , chromosome,
SNP and their portions in DNA sequence structure. A contingency table is a form
of table in a matrix layout that presents the frequency distribution of the variables.
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Then the next step involves building a predictive model primarily on a support vector
machine classifier that takes into account the input features identified here based on
genomic and epigenetic factors to train for predicting the early stage of MCI. More
details about how support vector machine classification is performed can be found
in Appendix A.

To generate training and test data sets for the SVM model the scikit Train-Test Split
function is used. The train-test split function can be used to help buiuld classification
or regression models which in turn and can be used as a basis for supervised learning
algorithms. The procedure involves taking a dataset and dividing it into two subsets.
In this project the 80: 20 ratio was used for train-test split evaluation. Common splits
are 80% training data and 20% testing data, called simple hold-out splits, from
sklearn.model_selection import train_test_split, X_train X_test y_train y_test =
train_test_split (X, y, test_size=0.20, random_state=33)

Figure 1. Train Test split function
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EXPERIMENTAL METHOD
As per initial steps for the experimental process the clean data sets are the must
prerequisite as it is directly responsible for the machine learning model, SVM binary
classifier.
The pre-processing and cleaning stage for ADNA GWAS data files. Each file was
in CSV format with a unique simple ID having around 75000 rows. Initially multiple
attributes were considered; GC score, SNP index, SNP name, Allele 1 plus, Allele
2 plus, Chromosome, SNP position, GPA score, cluster separation, SNP , Allele 1
plus Vs Allele 2 plus,etc. Statistical analysis of the feature set further narrowed down
to particular Chromosome type, SNP type & Positions.
['Chr'] == 4 & ['SNP'] == 13 ['SNP'] == 42
['Position'] == 21895517 or ['Position'] == 69033099 or
['Position'] == 116283010 or ['Position'] == 189690332
Some below substitutions were used here in the csv table as part of preprocessing
datasets.
0 = control, 1 = MCI, and 2 = AD 2.
For the nucleotides in the Allele columns, let A=1, C=2, G=3, T=4 and for the SNP
column an A/T = 14, an A/C =12, A/G=13,..., T/A=41, T/C=42 ... and so forth.
A Python-based support vector machine classified from scikit learn (CITE) was used
for training and prediction of AD+MCI from control (CN) and non-control MCI
/AD subjects). Generated a dataset that is separable and includes classes – so, in
short, an easy and binary dataset.
Next created an SVM with a polynomial kernel to train a classifier, however not
earlier than explaining the function of the kernel, also used C =1 and gamma to pass
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a crucial part of SVMs. Finally post-processing helped in producing an accuracy
confusion matrix as seen from high prediction model accuracy , lower counts on
false positive , false negative results around the decision boundary of the model.
When using SVM, necessarily using one of the kernels: linear, polynomial or
RBF=Radial Base Function (also called Gaussian Kernel). The larger the gamma,
the narrower the gaussian "bell" is.
Split Train and Test data :: 80:20 ratio implemented by below function in code.
x_train,x_test,y_train,y_test=train_test_split(X1,y,test_size=0.2)
SVM with a polynomial kernel to train a classifier
classifier = svm.SVC(kernel='poly', C=1, gamma=0.01, class_weight='balanced')
Results will be verified by splitting the data-sets into training and test sets to get a
more accurate assessment of SVM classifier's performance. Also SVM model binary
outcome for predicting early onset of cognitive impairment will be compared with
the actual ADNI sample dataset results to pick for any false positive and false
negative based on confusion matrix.

RESULTS
In machine learning ML , functions are independent single variables or features that
can be used as input to the system. In fact, when models make predictions, they use
these attributes (features) to make predictions.
The class label is a discrete attribute, and you want to predict its value based on the
values of other attributes. In this case, a controlled normal group CN or mild
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cognitive impairment MCI /AD are binary class names. The intent is to analyze a
function to calculate whether a person with a specific attribute value will be a
candidate for MCI / AD or not.
Experimentation results were derived with the built SVM binary classifier. Having
a polynomial kernel with C=1 and gamma=0.01, resulted in a prediction accuracy of
78.32 % or higher. Allele, Chromosome, SNP and SNP positions features were
identified as input to the binary ML model predicting either cognitive impairments
versus none for a certain control group.
How did you assess the quality and correctness of the obtained results?

To assess the quality and correctness of the obtained results , a two pronged approach
is taken. First from statistical analysis features were identified using statistical
models Contingency table, Chi square test, Pearson correlation test. The data used
in this research were obtained from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database / ADNI GO2 GWAS.
Next best of the features narrowed down from above statistical analysis were fed
into a predictive model based on a support vector machine (SVM) classifier that
takes into account the genomic variations and epigenetic factors to predict the early
stage of MCI/AD.
From these binary SVM classifiers an accuracy of around 78% were achieved to
predict early stages of MCI / AD versus normal people.
Below examples of features extracted from genomic variations were fed into inputs
to the SVM classifier.
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['Chr'] == T
&
['SNP'] == AG ['SNP'] == TC
&
['Position'] == 21895517 or ['Position'] == 69033099
or
['Position'] == 116283010 or ['Position'] == 189690332

A small change of adding C and gamma value seems to be bumping Up accuracy
considerably.
classifier = svm.SVC(kernel='poly', C=1, gamma=0.01, class_weight='balanced')
This comparatively higher accuracy for our experimental results.

EXPERIMANTAL RESULTS
As per observed experimental results statistical tools lead to better identification of
feature sets used in machine learning models. Contingency table, Chi square test,
correlation test, highlighted genomics variations with higher frequencies for
example chromosome-type, allele or around SNP for a group.
Results observed from Statistical tools / Chi-square test and Pearson correlation :
1- Here MCI group has a high number of nucleotides in the Allele type T.
>>> print(contingency Table)
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In statistics, a contingency table is a cross tabulation type of table in a matrix
format that displays the frequency distribution between the variables. Here it's
providing a picture of the interrelation between two variables that is the strong
relationship between MCI and Allele1 plus type G.
Allele1 - Plus 1 2 3 4
Group
0
475 380 452 943
1
1117 938 1255 2465
2
325 266 345 699

2Similarly, the MCI group can observe a high number of Chromosome 4
genomic types.
Here as per contingency table it's providing a picture of the interrelation between
two variables, that is a strong relationship between mild cognitive impairment
MCI and Chromosome type 4 .
>>> print(contingencyTable)
Chr 2 3 4 12
Group
0 149 300 1651 150
1 385 770 4235 385
2 107 216 1203 109

3MCI group has observed a high number of A/G genomic types for single
nucleotide polymorphisms SNP.
Here as per contingency table it's providing a picture of the interrelation between
two variables, that is a strong relationship between mild cognitive impairment
MCI and SNP 13 or A/G .
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>>> print(contingencyTable)
SNP 12 13 42 43
Group
0 300 1049 749 152
1 770 2694 1924 387
2 218 758 543 116
The chi-square test of independence further can be used to examine these above
stated relationships. Based on Chi-square statistics & p-value one can conclude that
a relationship exists between the categorical variables; that is the results are
significant or not.

Here objectives involve identifying some of the genomic variations, such as single
nucleotide polymorphisms (SNPs), allele , chromosome, epigenetic contributors to
MCI and AD that are beyond that related to Aβ and Tau. These areas of interest were
answered here with encouraging results showing positive prediction accuracy for
selected genomic features and strong potential to expand into research scoping
beyond Aβ and Tau. And can further expand into identifying more genomic
variations for developmental prediction models based classifiers.

CONCLUSION AND DISCUSSION
The proposed effort involved identifying some of the genomic variations, such as
single nucleotide polymorphisms (SNPs), allele , chromosome, epigenetic
contributors to MCI and AD that are beyond that related to Aβ and Tau.
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The project led to building a predictive model based on a support vector machine
(SVM) classifier that takes into account the above mentioned genomic variations
and epigenetic factors to predict the early stage of MCI/AD. Based on the results
from the SVM binary classifier it is evident that using certain genetic variations can
be used for predicting early onset of cognitive impairment diseases.
The research strategy used here can be helpful to engineer better mechanisms to
enhance classification models for early stage detection of cognitive impairments.

FUTURE WORK
Explore the genes the SNPs are associated with to see if there are metabolic
pathways involved or epigenetic relationships with other known causes or factors
related to AD/MCI. Secondly, increase sample size analyzed from ADNI DB. Next
explore and analyze potential secondary effects/medical-conditions such as other
diseases that might have influenced the observed results. Separate out MCI from AD
and explore predictions and results.
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APPENDIX A

Fig 2 .Separable Data for SVM classifier
The above figure depicts the use of a support vector machine (SVM) when data has
exactly two classes that are in here, two subjects control group (CN) Vs cognitive
impairment (MCI/AD). An SVM classifies data by finding the best hyperplane that
separates all data points of one class from those of the other class. The best
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hyperplane for an SVM means the one with the distinct margin between the two
classes. Margin means the width of the slab parallel to the hyperplane that has no
internal data points.
As with any supervised learning model, first train a support vector machine, and then
cross validate the classifier. Use the trained machine to predict new data. In addition,
to obtain acceptable predictive accuracy, test various SVM kernel functions, and
further tune the parameters of the kernel functions.
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